Silexon Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $15.4M

  • Investors
  • 8

Silexon General Information

Description

Developer of AI-empowered drug discovery technology for pharmaceutical companies. The company specializes in AI technologies including drug repositioning platforms, macro-molecular design models, and AI virtual molecule screening to assist the generic drug discovery process, providing pharmaceutical researchers with technical and AI-based data analysis support.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 317-321, 3/F, Building F7
  • No.9, Weidi Road, University City, Xianlin street, Qixia District
  • Nanjing, Jiangsu
  • China
Primary Industry
Discovery Tools (Healthcare)
Corporate Office
  • Room 317-321, 3/F, Building F7
  • No.9, Weidi Road, University City, Xianlin street, Qixia District
  • Nanjing, Jiangsu
  • China

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Silexon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 25-Jul-2021 $15.4M Completed Generating Revenue
1. Early Stage VC 23-Nov-2019 Completed Generating Revenue
To view Silexon’s complete valuation and funding history, request access »

Silexon Patents

Silexon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025000265-A1 Heterocyclic compounds usefull as sos1 inhibitor Inactive 28-Jun-2023
WO-2023138612-A1 Heterocyclic compounds useful as hpk1 inhibitors Inactive 19-Jan-2022
WO-2023125737-A1 Heterocyclic compounds and use thereof Inactive 29-Dec-2021
WO-2023284881-A1 Heterocyclic compounds useful as kras g12d inhibitors Inactive 16-Jul-2021
WO-2022262838-A1 Deuterated compounds useful as kras g12d inhibitors Inactive 18-Jun-2021 C07D519/00
To view Silexon’s complete patent history, request access »

Silexon Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Eight Roads Corporate Venture Capital Minority
F-Prime Venture Capital Minority
HSG (Hong Kong) Venture Capital Minority
Quan Capital Venture Capital Minority
Ascendin Fund Corporate Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Silexon FAQs

  • When was Silexon founded?

    Silexon was founded in 2018.

  • Where is Silexon headquartered?

    Silexon is headquartered in Nanjing, China.

  • What industry is Silexon in?

    Silexon’s primary industry is Discovery Tools (Healthcare).

  • Is Silexon a private or public company?

    Silexon is a Private company.

  • What is Silexon’s current revenue?

    The current revenue for Silexon is .

  • How much funding has Silexon raised over time?

    Silexon has raised $15.4M.

  • Who are Silexon’s investors?

    Eight Roads, F-Prime, HSG (Hong Kong), Quan Capital, and Ascendin Fund are 5 of 8 investors who have invested in Silexon.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process